Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61,778,278
-
Total 13F shares
-
36,998,812
-
Share change
-
+10,137,504
-
Total reported value
-
$327,811,496
-
Put/Call ratio
-
1050%
-
Price per share
-
$8.86
-
Number of holders
-
71
-
Value change
-
+$89,731,106
-
Number of buys
-
48
-
Number of sells
-
17
Institutional Holders of Aura Biosciences, Inc. - Common Stock (AURA) as of Q4 2023
As of 31 Dec 2023,
Aura Biosciences, Inc. - Common Stock (AURA) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,998,812 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, EVENTIDE ASSET MANAGEMENT, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, Medicxi Ventures Management (Jersey) Ltd, BlackRock Inc., VANGUARD GROUP INC, Nantahala Capital Management, LLC, GOLDMAN SACHS GROUP INC, and Regency Capital Management Inc.\DE.
This page lists
71
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.